1,377 research outputs found

    Invariance principles for self-similar set-indexed random fields

    Get PDF
    For a stationary random field (Xj)jZd(X_j)_{j\in\Z^d} and some measure m on Rd\R^d, we consider the set-indexed weighted sum process Sn(A)=jZdm(nARj)12XjS_n(A)=\sum_{j\in\Z^d}m(nA\cap R_j)^\frac12 X_j, where R_j is the unit cube with lower corner j. We establish a general invariance principle under a p-stability assumption on the X_j's and an entropy condition on the class of sets A. The limit processes are self-similar set-indexed Gaussian processes with continuous sample paths. Using Chentsov's type representations to choose appropriate measures m and particular sets A, we show that these limits can be Lévy (fractional) Brownian fields or (fractional) Brownian sheets

    Can we cure ATL: new drugs and targeting ATL stem cells

    Full text link

    Hepatitis C Virus Infection and Lymphoma

    Get PDF
    Apart from its well known role as an etiological agent for non-A and non-B viral hepatitis, there is growing evidence that hepatitis C virus is associated to B-cell non-Hodgkin lymphoma. The association between HCV and lymphoproliferative disorders has been recently postulated based on epidemiological data, biological studies and clinical observations. Although various subtypes of lymphomas appear to be associated to HCV, diffuse large B-cell lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia and marginal zone lymphoma appeared to be particularly represented among HCV-positive patients. The causative role of HCV in those disorders has been further supported by the response to antiviral therapy. Despite a better understanding of pathophysiological processes at stake leading from HCV infection to overt lymphoma, many issues still need to be further elucidated. Although HCV has been demonstrated to directly infect peripheral blood mononuclear cells both in vitro and, in some cases, in vivo, a strong body of evidence rather supports the hypothesis of an indirect transformation mechanism by which sustained antigenic stimulation leads from oligoclonal to monoclonal expansion and sometimes to lymphoma, probably through secondary oncogenic events. Here, we review epidemiological and biological studies, as well as clinical data on antiviral therapy, linking HCV-infection to B-cell non-Hodgkin lymphoma

    Current concepts regarding the HTLV-1 receptor complex

    Get PDF
    The identity of the Human T lymphotropic Virus type 1 (HTLV-1) receptor remained an unsolved puzzle for two decades, until the recent demonstration that three molecules, Glucose Transporter 1, Neuropilin-1 and Heparan Sulfate Proteoglycans are involved in HTLV-1 binding and entry. Despite these advances, several questions remain unanswered, including the precise role of each of these molecules during virus entry. In light of the most recent data, we propose a model of the HTLV-1 receptor complex and discuss its potential impact on HTLV-1 infection

    Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications

    Get PDF
    Cyclosporin-A has been known and used for a long time, since its “fast track” approval in the early 80's. This molecule has rapidly demonstrated unexpected immunosuppressive properties, transforming the history of organ transplantation. Cyclosporin's key effect relies on modulation on T-lymphocyte activity, which explains its role in the prevention of graft rejection. However, whether cyclosporin-A exerts other effects on immune system remains to be determined. Until recently, cyclosporin-A was mainly used at a high-dose, but given the drug toxicity and despite the fear of losing its immunosuppressive effects, there is nowadays a tendency to decrease its dose. The literature has been reporting data revealing a paradoxical effect of low dosage of cyclosporin-A. These low-doses appear to have immunomodulatory properties, with different effects from high-doses on CD8+ T lymphocyte activation, auto-immune diseases, graft-vs.-host disease and cancer. The aim of this review is to discuss the role of cyclosporin-A, not only as a consecrated immunosuppressive agent, but also as an immunomodulatory drug when administrated at low-dose. The use of low-dose cyclosporin-A may become a new therapeutic strategy, particularly to treat cancer
    corecore